Bain Capital Public Equity Management Ii, LLC Affimed N.V. Transaction History

Bain Capital Public Equity Management Ii, LLC

$1.99 Billion
Q3 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $1.57 Million - $3.36 Million	691,817 Added 118.8%	1,274,153 $3.53 Million
Q1 2022 May 16, 2022	SELL	$3.69 - $5.65 $6.61 Million - $10.1 Million	-1,790,763 Reduced 75.46%	582,336 $2.55 Million
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $6.58 Million - $8.66 Million	1,225,093 Added 106.71%	2,373,099 $13.1 Million
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $495,287 - $671,409	-89,402 Reduced 7.22%	1,148,006 $7.1 Million
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $1.25 Million - $1.84 Million	161,290 Added 14.99%	1,237,408 $10.5 Million
Q1 2021 May 17, 2021	SELL	$5.12 - $8.48 $1.49 Million - $2.47 Million	-291,779 Reduced 21.33%	1,076,118 $8.51 Million
Q4 2020 Feb 16, 2021	SELL	$3.16 - $7.03 $2.47 Million - $5.49 Million	-780,616 Reduced 36.33%	1,367,897 $7.96 Million
Q3 2020 Nov 16, 2020	SELL	$3.26 - $4.73 $302,162 - $438,414	-92,688 Reduced 4.14%	2,148,513 $7.28 Million
Q2 2020 Aug 14, 2020	SELL	$1.58 - $4.63 $66,718 - $195,511	-42,227 Reduced 1.85%	2,241,201 $10.3 Million
Q1 2020 May 15, 2020	BUY	$1.44 - $3.02 $1.82 Million - $3.82 Million	1,263,814 Added 123.95%	2,283,428 $3.61 Million
Q3 2019 Nov 14, 2019	SELL	$2.67 - $3.65 $1,602 - $2,190	-600 Reduced 0.06%	1,019,614 $3 Million
Q2 2019 Aug 14, 2019	BUY	$2.6 - $4.21 $2.65 Million - $4.3 Million	1,020,214 New	1,020,214 $2.93 Million

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

Tekla Capital Management LLC

586K
Shares

$2.04 Million
0.01% of portfolio
Act Capital Management, LLC Wayne, PA

309K
Shares

$1.07 Million
0.88% of portfolio
Telemetry Investments, L.L.C. New York, NY

200K
Shares

$696,000
0.39% of portfolio

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bain Capital Public Equity Management Ii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bain Capital Public Equity Management Ii, LLC with notifications on news.

Account